

Special Issue

New Insights in the Role of Myeloid-Derived Suppressor Cells (MDSCs) in Cancer

Message from the Guest Editor

In recent years, myeloid-derived suppressor cells (MDSCs) have attracted increasing interest as major players in modulating tumor onset and progression of cancer. Although the physiopathology of MDSCs is still partially elusive, there is common agreement that these cells contribute to tumors pathogenesis through their immunosuppressive and pro-neoangiogenic activities. In keeping with this notion, previous studies demonstrated that the frequency of circulating MDSCs represents a reliable predictor of a negative outcome and response to therapy both in solid cancers and in hematological malignancies. Therefore, MDSCs could become potential targets for future therapeutic strategies aimed at favoring their differentiation into mature cells or at counteracting their immunosuppressive and neoangiogenic activity or at inhibiting their ability to migrate from the bone marrow (BM) to peripheral organs. In this Special Issue of *Cancers*, we welcome original research articles, reviews and perspectives that provide an overview of the most recent advances involving MDSCs in hematological malignancies and solid cancers.

Guest Editor

Dr. Rita Campanelli

Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

Deadline for manuscript submissions

31 May 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/212686

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)